S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

Similar documents
S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

Carcinoma of the Urinary Bladder Histopathology

Carcinoma of the Renal Pelvis and Ureter Histopathology

*OPERATIVE PROCEDURE. Serum tumour markers within normal limits S1.04 PRINCIPAL CLINICIAN

Gastric Cancer Histopathology Reporting Proforma

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

GUIDELINES ON PROSTATE CANCER

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

Diagnosis, pathology and prognosis including variant pathology

Vulva Cancer Histopathology Reporting Proforma

Update on Reporting Prostate Cancer Pathology

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Definition of Synoptic Reporting

Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD

GUIDELINEs ON PROSTATE CANCER

Recommendations for the Reporting of Prostate Carcinoma

Prostate Case Scenario 1

Collaborative Staging

TOPICS FOR DISCUSSION

Urinary Bladder, Ureter, and Renal Pelvis

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Descriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

11/21/13 CEA: 1.7 WNL

SEER Summary Stage Still Here!

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA

A215- Urinary bladder cancer tissues

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma

Prognostic factors of genitourinary tumors: Do we have to care?

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

ACRIN 6666 Therapeutic Surgery Form

PROSTATE CANCER (RADICAL PROSTATECTOMY) STRUCTURED REPORTING PROTOCOL (3rd Edition 2018)

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do?

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Neoplasms of the Prostate and Bladder

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

Kidney Case 1 SURGICAL PATHOLOGY REPORT

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

FNA Thyroid Cytology Structured Reporting Proforma

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Chapter 2. Understanding My Diagnosis

Case Scenario 1: Breast

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Boot Camp Case Scenarios

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Diagnosis of prostate cancer

Prostate Overview Quiz

UICC TNM 8 th Edition Errata

New research in prostate brachytherapy

LOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.

Prostate MRI for local staging and surgical planning in prostate cancer

The pathology of bladder cancer

Protocol for the Examination of Specimens from Patients with Carcinoma of the Prostate Gland

VULVAR CARCINOMA. Page 1 of 5

Enrollment Form: Pancreas

Large blocks in prostate and bladder pathology

46. Merkel Cell Carcinoma

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

Disease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy

47. Melanoma of the Skin

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

PROSTATE CANCER (TRANSURETHRAL RESECTION AND ENUCLEATION) STRUCTURED REPORTING PROTOCOL (1 st Edition 2018)

Protocol applies to specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood.

25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES

Case Discussions: Prostate Cancer

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

Disclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None

L ARYNX S TAGING F ORM

PLACE LABEL HERE. ACRIN 6659 Registration/Eligibility Institution

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma

Staging and Grading Last Updated Friday, 14 November 2008

Transcription:

Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous Status Aboriginal but not Torres Strait Islander origin Torres Strait Islander but not Aboriginal origin Both Aboriginal and Torres Strait Islander origin Neither Aboriginal nor Torres Strait Islander origin Not stated/inadequately described Patient identifiers e.g. MRN, IHI or NHI (please indicate which) Date of request S1.03 Accession number Requesting doctor - name and contact details Clinical information *Previous history of prostate cancer (include Gleason grade & score of prev. specimens if known) S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS *Previous biopsy (specify date and where *Previous therapy Macroscopic findings S2.01 SPECIMEN LABELLED AS *Other *PRE-BIOPSY SERUM PSA ng/ml S2.02 *SPECIMEN WEIGHT (IE WEIGHT OF PROSTATE WITHOUT SEMINAL VESICLES) g NEW PRIMARY LESION OR RECURRENCE (if previous focal therapy) New primary Recurrence - regional, describe G2.01 *SPECIMEN DIMENSIONS (PROSTATE) length x width x thickness Recurrence - distant, describe S2.03 *SEMINAL VESICLES Absent (partially or completely resected) Vers. 3.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 3rd Edition Page 1 of 5

G2.02 MAXIMUM DIMENSION OF SEMINAL VESICLE Left Right S2.04 *LYMPH NODES Absent (partially or completely resected) G2.03 *LATERALITY Left Right Bilateral Other S2.05 *BLOCK IDENTIFICATION KEY G3.02 TUMOUR LOCATION Largest nodule located by quadrant Right anterior Right posterior Left anterior Left posterior Largest nodule located by plane Apex Mid Base of prostate Other nodules >10 in diameter None identified Location by plane and quadrant: Right anterior Right posterior Left anterior Left posterior Apex Mid Base of prostate G3.03 *INTRAGLANDULAR EXTENT No tumour identified Tumour identified, specify value and units G2.04 ADDITIONAL MACROSCOPIC COMMENTS Other units, specify ml(cc) S3.02 *HISTOLOGICAL GRADE (REFER P5) *Gleason score Microscopic findings Indeterminate, specify reason S3.01 *HISTOLOGICAL TUMOUR TYPE G3.01 OF TYPE Adenocarcinoma (Acinar) Other, specify *Primary pattern/grade 1 2 3 4 5 *Secondary pattern/grade 1 2 3 4 5 Tertiary pattern/grade (Only record for tertiary pattern 5. If present, record method used to determine tertiary grade.), record methodology G3.04 *MAXIMUM SIZE OF DOMINANT NODULE Indicate how Gleason score is being reported: Highest score tumour (if it is smaller than the largest) Composite (global) score Vers. 3.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 3rd Edition Page 2 of 5

*International Society of Urological Pathology (ISUP) Grade (Grade Group) ISUP Grade (Grade Group) 1 (G. score 6) ISUP Grade (Grade Group) 2 (G. score 3+4=7) ISUP Grade (Grade Group) 3 (G. score 4+3=7) ISUP Grade (Grade Group) 4 (G. score 8) ISUP Grade (Group Group) 5 (G. score 9-10) Indeterminate, specify reason S3.05 *MARGIN STATUS Not involved Indeterminate Involved S3.06 *LOCATION(S) OF +VE MARGIN(S) Indicate how ISUP score is being reported: Highest score tumour (if it is smaller than the largest) Composite (global) score G3.07 *EXTENT OF MARGIN POSITIVITY (If > 1 positive margin, extent should reflect cumulative length) <3 linear extent 3 linear extent G3.05 *PERCENTAGE GLEASON PATTERN 4/5 (APPLICABLE FOR GLEASON SCORE 7) Indicate how G. score 4/5 is being reported: Highest score tumour (if it is smaller than Carcinoma as a whole the largest) G3.08 *GLEASON PATTERN OF TUMOUR PRESENT AT POSITIVE MARGIN (If >1 pattern at margin select highest) Gleason pattern 3 Gleason pattern 4/5 G3.09 *TYPE OF MARGIN POSITIVITY Extraprostatic (EPE) Intraprostatic (capsular incision) S3.03 *EXTRAPROSTATIC EXTENSION Indeterminate S3.07 *SEMINAL VESICLE INVASION Not applicable (*Refers to rare cases where seminal vesicles are not included in specimen) S3.04 *EXTENT OF EPE Established (Non-focal) G3.06 *LOCATION(S) OF EPE Focal G3.10 SITE OF SVI Left side Right side Both sides S3.08 *URINARY BLADDER NECK INVASION Not applicable (*Refers to cases where bladder neck is not included in specimen) G3.11 *INTRADUCTAL CARCINOMA OF PROSTATE Vers. 3.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 3rd Edition Page 3 of 5

S3.09 *LYMPH NODES STATUS *Number of lymph nodes examined Synthesis and overview S5.01 *PATHOLOGICAL STAGING (AJCC 8TH EDITION)** (refer p5) *Number of positive lymph nodes *Primary tumour (T) *Regional lymph nodes (N) G3.12 *LATERALITY *Distant metastasis (M) Not applicable OR Left Bilateral Right Other G3.13 *MAXIMUM DIMENSION OF LARGEST DEPOSIT S5.02 YEAR AND EDITION OF STAGING SYSTEM G5.01 DIAGNOSTIC SUMMARY Include specimen type, tumour type, Gleason score and/or ISUP grade, tumour stage, involvement of surgical margins S3.10 *LYMPHOVASCULAR INVASION Indeterminate G3.14 ADDITIONAL MICROSCOPIC COMMENT S5.03 OVERARCHING COMMENT G5.02 PROSTATE CANCER (RADICAL PROSTATECTOMY) STRUCTURED REPORTING PROTOCOL (3rd Edition 2018) Worksheet prepared by: On: Vers. 3.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 3rd Edition Page 4 of 5

HISTOLOGICAL GRADE ISUP grading system, radical prostatectomy specimens ISUP grade (Grade group) Gleason score Definition Grade 1 2-6 Only individual discrete wellformed Grade 2 3+4=7 Predominantly wellformed with lesser component (*) of poorlyformed/fused/cribriform Grade 3 4+3=7 Predominantly poorlyformed/fused/cribriform with lesser component (**) of wellformed Grade 4 4+4=8 Only poorly-formed/fused/ cribriform 3+5=8 Predominantly wellformed and lesser component (*) lacking 5+3=8 Predominantly lacking and lesser component (**) of wellformed Grade 5 9-10 Lack gland formation (or with necrosis) with or without poorly formed/ fused/cribriform * A high-grade pattern is included in the grade only if it is at least 5. If less than 5, it should be mentioned separately in the report. ** The low-grade pattern is included in the grade only if it is at least 5. Gleason scoring of unusual patterns Pattern Morphology Coent Vacuoles Mucin extravasation Mucinous fibroplasia Glomeruloid structures Foamy gland change Small cell neuroendocrine Cytoplasmic change seen in all grades Collagenous micronodules Grade as if vacuoles were absent, on the underlying Grade as 4 Do not assign a grade PATHOLOGICAL STAGING (AJCC 8 TH EDITION) ## m - multiple primary tumours r - recurrent y - post neoadjuvant therapy Primary tumour (pt) TX Primary tumour cannot be assessed T0 No evidence of primary tumour T2 Organ confined T3 Extraprostatic extension T3a Extracapsular extension (unilateral or bilateral) or microscopic invasion of bladder neck T3b Tumour invades seminal vesicle(s) T4 Tumour is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, levator muscles, and/or pelvic wall Regional lymph nodes (pn) NX Regional lymph nodes were not assessed N0 No regional lymph nodes N1 Metastases in regional lymph node(s) Distant metastasis (pm)* M1 Distant metastasis M1a Non-regional lymph node(s) M1b Bone(s) M1c Other site(s) with or without bone disease * Note: When more than 1 site of metastasis is present, the most advanced category is used. pm1c is the most advanced category. ## Used with the permission of the American Joint Coittee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com. Vers. 3.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 3rd Edition Page 5 of 5